Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | BGB3245 |
Synonyms | |
Therapy Description |
BGB3245 inhibits RAF dimer formation, which may lead to inhibition of Erk signaling and cell growth (PMID: 29880583). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BGB3245 | BGB-3245|BGB 3245 | BGB3245 inhibits RAF dimer formation, which may lead to inhibition of Erk signaling and cell growth (PMID: 29880583). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF L514V BRAF V600E | melanoma | predicted - sensitive | BGB3245 | Preclinical - Cell culture | Actionable | In a preclinical study, BGB3245 resulted in similar inhibition of Erk phosphorylation and colony formation in melanoma cells expressing BRAF L514V in cis with V600E and cells expressing BRAF V600E alone in culture (PMID: 29880583). | 29880583 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04249843 | Phase I | BGB3245 | Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors | Recruiting | USA | 1 |